Compass Therapeutics, Inc Investor Event Transcript, Nov 11, 2026
Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics is re-engaging FDA on Tevesimig for biliary tract cancer and targets a BLA submission in the first half of the coming year. The company reported $163 million in cash, well into 2028. AI summary
Conference Transcript - CMPX 2026-11-11
Stephen Willey, Analyst — Stiefel
Yeah, the chairs are a little rough. All right. Good morning, everyone. I'm Stephen Willey, one of the senior analysts here at Stiefel. I'm glad to have with us. In the next session, Tom Schuetz, who's the CEO of Compass Therapeutics. We're going to have a casual discussion. If anyone has a question, feel free to raise your hand. Tom, thanks for coming, as always, and any opening statements you'd like to make before we jump right into Q&A.
Thomas Schuetz, CEO
Sure. So again, thanks for having us here. Always happy to come. So for those of you who don't know, Compass, we're located in Boston. We're a monoclonal antibody discovery and development company in oncology. We've got four drugs in the clinic, which we'll talk about today. Our lead program, Tevesimig, a couple of weeks ago, we presented data from a randomized trial at ESMO, and we simultaneously published all that data in the Journal of Clinical Oncology. on October 24th, and we're sort of in the middle of re-engaging with FDA right now in order to have a conversation about a path forward to get this drug approved for the treatment of patients with biliary tract cancer.
Stephen Willey, Analyst — Stiefel
Um, and congrats on the JCO publication. I know that kind of puts a good bow on companion. Yeah, thank you. Just curious. I know that there were kind of some incremental pieces of information that were disclosed and came out of both the presentation and the manuscript. Anything you, you want to highlight there?
Thomas Schuetz, CEO
Sure. Um, you know, I think. Interestingly, so you are correct, you know, getting a publication in JCO simultaneously with an ESMO presentation does require some aligning of the planets. And, you know, fascinatingly, during the review of the draft JCO manuscript, one of the reviewers specifically asked for the two-stage estimation method to do the crossover correction on OS. And that, you know, I think the, you know, the question, you know, about the ITT analysis versus the crossover analysis, you know, so that, you know, clearly showed, you know, that the hazard ratio is below one. Yeah, but I think as you and I have talked about before, right, the intent to treat analysis is sort of anything but that, right? You know, the patients initially randomized to the control arm were not intended to be treated with Tivesimeg, and so that analysis is kind of... Yeah, really, it's really irrelevant. So, you know, I think what we showed, not only in the JCO paper, but also in the ESMO presentation, you know, the patients, if you got to Vesemig at any time during this study, you lived longer. And, you know, we need to, you know, just be clear about that and, you know, talk about that, you know, more clearly in our regulatory conversations.
Stephen Willey, Analyst — Stiefel
Maybe this is a little bit too much of a statistically wonky question, but how does this second? Post hoc analysis that was requested to look at the impact of patient crossover. How did that look, or how is that mechanistically or philosophically different from the rank preserved model that you had pre-specified within the stats plan?
Thomas Schuetz, CEO
I'm going to pounce on your use of the word wonky, if you don't mind, because I'm not going to be fully able to go into that wonk. My understanding is for the RPSFT, when the ITT hazard ratio is above one, the mathematics of that can't work.
Stephen Willey, Analyst — Stiefel
Yep.
Thomas Schuetz, CEO
So conceptually, the two methods are similar, which is in the two-stage, quote-unquote, the first stage is a modeling exercise to determine how patients did after crossing over to Tevessemin, the control patients. Once you model that, then you use that model in the second stage, two stage, to calculate something called counterfactual survival, which simply adjusts patient's survival in the control arm. To a point where the assumption is how they would have done if they had not crossed over. So that is my conceptual understanding of that method. I certainly could not describe them.
Stephen Willey, Analyst — Stiefel
Okay. I thought it was interesting that the hazard ratio of that post not of that post hoc kind of perfectly aligned with what. Astra tried to do in that Tropion breast trial where they did that post hoc on survival, which was a co-primary with no crossover. I know we've talked about this, but that post hoc was also 0.85, and it was part of the regulatory submission.
Thomas Schuetz, CEO
Yeah, so we, by the way, you didn't ask this, but that was not included in our regulatory submission in the summertime. So, you know, that's something that we're sort of doing right now. You know, sort of we're in the, we're right in the middle today of re-engaging with FDA. And, you know, how we, you know, so we need to present that data very clearly to FDA.
Stephen Willey, Analyst — Stiefel
Okay. And maybe before we get into that re-engagement, you know, I thought in the presentation and the management, We also learned a little bit more about these crossover patients with respect to their patient baselines, the subsequent therapy that they received. The response that they achieved once they crossed over, and I guess I'm still really surprised by the fact that these patients did as well as they did from a survival perspective. Are you still trying to do some of the work, some of the biological work to understand, you know, if this hypothetical priming effect is real?
Thomas Schuetz, CEO
You bet. So we've done a fair amount of work over the past several months, you know, continuing to analyze, you know, the data that we have, you know, both serum and biopsy specimens, you know, to try to help us get at this answer. And by the way, I thought the discussant. Of the ESMO presentation, right? He was spot on because he specifically highlighted this.
Stephen Willey, Analyst — Stiefel
Correct.
Thomas Schuetz, CEO
You know, he said, hey, there are some patients here who did staggeringly well, right? It is incumbent upon us, you know, to do everything we can to try to figure that out. So I think, you know, maybe early next year, hopefully at a scientific meeting, you know, we're hoping to present, you know, Some of that work, but it's a big hypothesis, right? You and I have talked about this before, right? You know, how, you know, does... Two months of Paclitaxel alter angiogenesis in the tumor microenvironment that makes Tavessimig work better. You know, my God, that's a complicated hypothesis. But I think we have to do everything we can to figure it out.
Stephen Willey, Analyst — Stiefel
I think in the presentation, maybe just kind of last question related to this, but we also saw... Thank you. Granular safety data for the first time. And I know it's always really challenging to interpret safety data in the second-line biliary cancer patients. They're incredibly, you know, complex. But just how do you think about, you know, the... The safety tolerability data just in the context of the broader risk-benefit that you think exists here.
Thomas Schuetz, CEO
Yeah, I think it's a good question. I think the real difference between Tevesimig and other VEGF-targeted drugs, I think, is hypertension. So I think that's the real difference. So we talked to a lot of docs about that at ESMO. We probably had, we probably met with like 30 docs, you know, or something like that, you know, at ESMO, you know, just thinking about, you know, developing hypertension management guidelines, you know, and how we think about that, you know, compared with other sort of VEGF targeted agents. I think that's what we're going to need to do.
Stephen Willey, Analyst — Stiefel
Okay. So maybe just on the re-engagement side, right? You've talked previously about wanting to meet with them again to discuss accelerated approval prospects. Where are you in that process right now? When should that next meeting occur?
Thomas Schuetz, CEO
So... You know, unfortunately, in the summertime, we were not afforded a meeting, so we never, all of the communications with FDA were via email. So, you know, I think, so, I know this, I apologize, Steve, I'm not trying to sound trite here, but. Our first goal for the meeting is to have a meeting. So, yeah, we just, we want to have a live conversation about the data and, you know, put it in context and, you know, put it in context of the. You know, very important meta-analysis that was published at the end of 2025 by Castette et al., which showed that that's a 10,000-patient meta-analysis that showed that PFS hazard ratio of less than 0.61 was predictive of an OS benefit. You know, that's an extremely important paper. That we have to sit down with FDA and have a conversation about. You know, we've got a hazard ratio of 0.44 on PFS, you know, following the publication of a meta-analysis with, you know, 10,000 patients. So, you know, we have to sit down and put those data in context. And I think that. Look, as you know, once a quote-unquote surrogate endpoint is validated, it is no longer a surrogate, right? You know, I think probably the best example of that ever is probably serum cholesterol, right? Yeah, when cholesterol-lowering drugs were first being developed, everybody said, blah, blah, blah, blah, blah. Serum cholesterol is a surrogate. Well, not anymore. Right? Because it was validated. So I would just like to be able to have that conversation with FDA about PFS as a validated surrogate in this disease. And if FDA says, all right, let's talk about accelerated approval, I'll be like, okay, let's talk about a confirmatory study and what that might look like.
Stephen Willey, Analyst — Stiefel
What might that confirmatory study look like?
Thomas Schuetz, CEO
So I think there may be Three possibilities. I think probably the simplest and most straightforward design would be Tevesimig plus Paclitaxel versus Fulfax in the second-line setting. We had some conversations with folks in the EU when we were in Madrid a couple weeks ago at ESMO about that study, and there are folks in the EU who are very interested in conducting that study. So the regulatory significance of that study would maybe be twofold. That would get us EU approval and would be a confirmatory study for accelerated approval in the U.S. Obviously, that's a straight-up one-to-one randomization with OS as the primary endpoint and obviously no crossover. Another potential study designed would be a frontline study. We've got an IST ongoing in MD Anderson where we're adding tevesemig to the Topaz 1 regimen of gem-sister volumab, so there'd be a very straightforward design that would come out of that. That's probably a bigger, longer, more expensive study, but I think that's something on the table. You know, we could also potentially do Tevesimig Paclitaxel versus Paclitaxel, you know, a similar design to Companion O2 with OS as the endpoint. There's probably not a lot of enthusiasm for that study because we've already demonstrated, you know, a treatment effect in Companion O2, but I just want to be complete, you know, with the question that you asked.
Stephen Willey, Analyst — Stiefel
Okay. And so you're going to go to this next, or I guess first meeting now with FDA, hopefully, with this confirmatory trial design in hand, or I guess some options in hand. And then is the expectation here still that we should expect a BLA submission sometime in the first half of next year, kind of regardless of whatever? It happens from an FDA feedback perspective.
Thomas Schuetz, CEO
So I would generally say yes. But to be fair to the way you ask the question, you know, if we have a sit down meeting with the FDA and they say, you know, no way, no how, no chance.
Stephen Willey, Analyst — Stiefel
Right.
Thomas Schuetz, CEO
I mean, you know, gosh, we would have to listen to that, I think. You know, especially if they said, you know, if you send this in, we're going to send it back to you. Right? So I think, you know, I think absent that, we would move forward with a BLA submission in the first half of the coming year.
Stephen Willey, Analyst — Stiefel
Okay. And you mentioned the frontline setting as potential, as a potential. Place in which to run a confirmatory trial, and you referenced the MD Anderson-sponsored trial that's ongoing. Should we expect to see any data from that?
Thomas Schuetz, CEO
So I met with the PI from that study also at ESMO a couple weeks ago. So we're clearly seeing efficacy in that study coming clearly. We're now going to expand to some additional sites in the MD Anderson network. I'd like to get that study fully enrolled in the coming year. And then the primary efficacy endpoint of that study is a six-month PFS landmark. So I would love to be close to that by the end of the coming year. That would be the goal.
Stephen Willey, Analyst — Stiefel
Any thoughts on the Acheso phase three?
Thomas Schuetz, CEO
Oh, yeah.
Stephen Willey, Analyst — Stiefel
The biliary data that we saw, and it looks like that data would suggest that we're going to see this agent, you know, become standard of care at some point within the major farmer markets. How do you think about having VEGF targeting in the front line, and then what the implications, if any, of that might be for Tovesomega as a second-line agent?
Thomas Schuetz, CEO
Sure. So, of course, I was at that presentation two and a half weeks ago, so I was, like, super happy with that result for two main reasons. So one, it showed that VEGF targeting in this disease is a valid mechanism to target, which has never been shown before. So I was super happy about that. Secondly, we have our own PD-1 VEGF bispecific, and this is just more data to suggest that this is a real class of drug. You know, the second half of your question, honestly, I don't really worry about too much because I think how many diseases are there with, you know, VEGF after VEGF after VEGF is, you know, part of standard treatment, right? Colorectal cancer. Frontline, second line, third line, fourth line therapy consecutively all have VEGF targeting. Chemo Bev, Chemo Bev, Chemo Bev, followed by VEGF TKIs, renal cell. How many VEGF-targeted TKIs are there in renal cell that are simply used consecutively? You know, so VEGF after VEGF, that's just not something I worry about.
Stephen Willey, Analyst — Stiefel
That's a good point. I remember you showed that in your Tovesimig later line colorectal data, right, where most of the patients had seen two-plus, you know, prior lines of BEV, and you were still able to confer, you know, responses in some patients in stable disease.
Thomas Schuetz, CEO
Similarly, in our phase one study with gastric, patients had ramucerumab, a VEGF receptor-targeted agents, followed by Tevesimig, and they still respond. So it's just not something I really worry about.
Stephen Willey, Analyst — Stiefel
Gastric, I know that you had highlighted gastric and ovarian as maybe some other tumor types in which you would like to do some more development work with Tovesimig. Are those plans still in place?
Thomas Schuetz, CEO
So where we are today is, you know, I think we're, we've had so much investigator interest in Tevesimeg. You know, we're starting and have started and are continuing to start investigator-sponsored studies. And I think we're probably going to use those ISTs as our quote-unquote signal finding. Okay. All right. So we've got a second-line gastric study on the table, which is quite fascinating. You know, we're going to do Paclitaxel to Vesemeg with 8371, our PD-1, PD-L1 by specific. We've also got a glioblastoma study ongoing. And as you and I have talked about this before, I am not afraid for one second. To use the word glioblastoma in a sentence, you know, it's just another bad disease, right? So that study's ongoing at Wash U in St. Louis, combining Tevesimig with 471. You know, met with the PI of that study also in Madrid two and a half weeks ago, and we're sort of clearly seeing signals in that study already. We're also going to do a second-line colorectal cancer study combining Tevesimig with Fulfuri, you know, which is also something, you know, very, very interesting to think about. And that's those two, the gastric and the colorectal, are going to get started very soon.
Stephen Willey, Analyst — Stiefel
Okay, and both ISTs.
Thomas Schuetz, CEO
Both ISTs, correct.
Stephen Willey, Analyst — Stiefel
Okay. You mentioned the PD-1 VEGFA that you have. This is CTX 10726. I know you just presented some of the preclinical data for this at CITSI. I think in my naive interpretation of it certainly appears to support a case for mechanistic differentiation. How do you, you know, view this to be different than some of the other molecules in this class? And maybe more importantly, why do you think that differentiation will matter clinically?
Thomas Schuetz, CEO
Sure. Don't be so hard on yourself. You're not naive. Come on. So you are correct. We clearly have mechanistic differentiation. So I think one of the things that maybe we have not made clear enough in the past is the PD-1 binding end. of our PD-1, PD-L1, and our PD-1-VEGFA bispecifics are the same. And with both of those drugs, we've now identified PD-1 stripping as part of the mechanism of action. So I think we can now say that PD-1 stripping is a characteristic of our PD-1 binding antibody. And I think that's very important. So, you know, we have done some comparison studies. Not every PD-1 binding antibody does this. So it's something characteristic of that drug. And yes, you know, we believe that we are mechanistically differentiated. Now, you know, gosh, look, I have to be fair here, right? Ivanesimab. I don't know how many patients have been treated in clinical trials with ibanesimab. Thousands and thousands, right? So in order to convert our scientific mechanistic differentiation, you know, into clinical differentiation, it's going to take some time. But, you know, I think it's a good place to start.
Stephen Willey, Analyst — Stiefel
Okay. I know you have the phase one dose escalation that's ongoing. You know, I guess it's interesting, you know, your dose escalation schema, you're topping out at 10 mg per kg, which, you know, we know is, like, two to three times lower than where the other sponsors seem to be pushing their PD-1 VEGFA's in terms of dose, just any. Thoughts around why you're at such a lower top dose relative to what we've seen from the class?
Thomas Schuetz, CEO
Yeah, so very, very complicated question for sure. One of the things that has very, very much perplexed me in this class of drugs is the doses that are used. I mean, these are just staggeringly high doses. I mean, you know, think about this, like 20 to 30 mg per kg, you know, if you're an 80-kilogram patient, right, we're talking about 2 to 3 grams of antibody for the dose? I mean, that's like, that's like, it's crazy. So I don't really understand the dosing. To be fair to your question, you know, I think once we, you know, get through the dose escalation, you know, we'll take a look at all the data, you know, and maybe we'll go to 20. I don't know. You know, we haven't really made that decision yet, but I'd like that decision to be data driven, you know, PK, PD, et cetera.
Stephen Willey, Analyst — Stiefel
Okay. Is there any biomarker or translational data that you can? Um, evaluate in this, in this phase one dose escalation trial that would somehow either inform or validate this PD one cleavage.
Thomas Schuetz, CEO
We're looking at that right now. Yes.
Stephen Willey, Analyst — Stiefel
Okay. And then when might we expect to see the phase one dose escalation?
Thomas Schuetz, CEO
Yeah, so we'll give a little status update on that before JP Morgan. We're moving into the third dosing cohort now. I haven't seen any dose-limiting toxicities. Hopefully, we'll be in the fourth dosing cohort before the end of the year. And we'll give an update on some potential efficacy
Stephen Willey, Analyst — Stiefel
Okay. And then how do you think about the next development steps? Obviously, single agent dose expansion, like you kind of need to do some box checking there, but the field's moving towards combos. And you've got a few assets in your pipeline that would seemingly be interesting. Right. So.
Thomas Schuetz, CEO
Yes, we will have some cohort expansions to do, and I think that'll be very, very important to do that work. You also are, of course, correct. The entire field seems to be moving toward combinations with ADCs and other combinations. You know, I think, you know, we also, you know, have shown some data about, you know, the combination with our own CD137 agonist antibody 471. You know, I think that's something to think very hard about.
Stephen Willey, Analyst — Stiefel
Mm-hmm.
Thomas Schuetz, CEO
You know, would there be a way to, you know, maybe do a collaboration, you know, combining it with some ADCs or other targeted agents? You know, we've had some inbound on this recently that we're evaluating, you know, for combining that drug, you know, with some targeted agents, and we're evaluating that right now.
Stephen Willey, Analyst — Stiefel
Okay. There's obviously, you know, this is, I don't want to say crowded, but there's a lot of different iterations of the PD-1 VEGFA mechanism in the clinic. It's crowded, right? You said it. But there's obviously still, you know, a lot of... A lot of strategics, big biotech, big pharma, you know, who have very large oncology footprints who don't yet have one of these things. So how would you characterize and not necessarily from a. Inbound interest perspective, but how would you just kind of characterize the strategic interest that exists around this class? And if you want to contextualize that with respect to inbound interest, feel free.
Thomas Schuetz, CEO
Yeah. So, you know, I think the way you summarized it was very, very good. Right. And I think the more. The more data that are generated with Ivanesimab, the better it is for everybody, right? So at this conference earlier today, in one of our meetings with an investor, an investor said to me, oh, a year ago, I was talking to Big Pharma X executive who said they weren't sure if this was going to be a class of drugs. And last week, I talked to Big Pharma X executive who said, oh, yeah, this is definitely a class of drugs. So, you know, I think, you know, the fact that, you know, so we've got Merck, Pfizer, BMS. I'll put Summit in that category as well, AbbVie. So there are more not on the list than on the list. So it sort of reminds me in some ways of the early days of PD-1 targeting, right? You know, in the early days of PD-1 targeting, which is, you know, only 10 years ago, people are like, oh, geez, we've got Pembro, we've got Nevo, what else do we need? Well, today, gosh, there's like, I think, eight PD-1 pathway targeting drugs approved in this country, either PD-1 or PD-L1 targeted. So, you know, I think there's plenty of room for differentiated and better drugs.
Stephen Willey, Analyst — Stiefel
Okay. 8371, you mentioned it. It's a little bit more advanced than PD-1 VEGFA. You have it in dose expansion now. Just when should we see the next update, and what should that update look like in terms of what we're going to learn?
Thomas Schuetz, CEO
So, I think we'll give, again, a status update on that before the J.P. Morgan conference, for sure. You know, just where we are with enrollment. The study's been enrolling quite well. I think we've got, you know, mid-20s patients enrolled in the cohort expansion. You know, clearly, you know, we're seeing additional signals of efficacy, which is great to see. You know, and we'll probably, you know, give an update on, you know, sort of where we might take that program, I think. So, you know, just to, you know, probably that study will probably be fully enrolled in the coming year. So a full data set is probably second half of next year. But I think in the coming months, we'll definitely give an update about where we are with that program.
Stephen Willey, Analyst — Stiefel
Okay. And maybe last pipeline question, you did end up initiating that CTX471 trial in NCAM positive tumors.
Thomas Schuetz, CEO
Yes, that study is now opening and recruiting patients.
Stephen Willey, Analyst — Stiefel
Okay. And is that on the docket for maybe an update before the end of next year?
Thomas Schuetz, CEO
I think before the end of next year, yes. Yes, next year, yes, not this year.
Stephen Willey, Analyst — Stiefel
All right. Balance sheet and just kind of what that allows you to execute on.
Thomas Schuetz, CEO
Yeah. Financials two days ago, $163 million, you know, cash well into 2028. So, you know, executing on all these programs, you know, getting us sort of multiple inflection points, I think, in the coming year.
Stephen Willey, Analyst — Stiefel
Okay. Anything we didn't talk about that you want to highlight? We're good.
Thomas Schuetz, CEO
No, this is great. Yeah.
Stephen Willey, Analyst — Stiefel
Thanks again. Thank you, everyone.